BCAB
BioAtla, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+2.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.5M | 2.0M | 11.0M | — | — |
| Cost of Revenue | 8.9M | 43.1M | 925.0K | 1.2M | 1.2M |
| Gross Profit | (353.0K) | (41.1M) | 10.1M | (1.2M) | (1.2M) |
| Operating Expenses | |||||
| R&D Expense | 25.5M | 43.6M | 63.1M | 103.7M | 79.3M |
| SG&A Expense | 15.2M | 17.6M | 21.8M | 26.0M | 28.8M |
| General & Admin Expense | 15.2M | 17.6M | 21.8M | 26.0M | 28.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (9.4M) | (43.0M) | (925.0K) | (1.2M) | (1.2M) |
| Total Operating Expenses | 31.3M | 18.2M | 84.0M | 128.5M | 106.9M |
| Cost and Expenses | 40.1M | 61.3M | 84.9M | 129.7M | 108.1M |
| Operating Income (EBIT) | (31.6M) | (59.3M) | (73.9M) | (129.7M) | (108.1M) |
| Non-Operating | |||||
| Interest Income | 263.0K | 843.0K | 3.4M | 6.3M | 1.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 263.0K | 843.0K | 3.4M | 6.3M | 1.6M |
| Other Non-Op Income/Expense | 171.0K | (302.0K) | 4.2M | 6.2M | 1.7M |
| Non-Operating Income (excl Interest) | (2.3M) | 302.0K | (4.2M) | (6.2M) | (1.7M) |
| EBT (Pre-Tax Income) | (31.5M) | (59.6M) | (69.8M) | (123.5M) | (106.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (31.5M) | (59.6M) | (69.8M) | (123.5M) | (105.3M) |
| Earnings from Cont. Ops | (31.5M) | (59.6M) | (69.8M) | (123.5M) | (106.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (31.5M) | (59.6M) | (69.8M) | (123.5M) | (106.5M) |
| Per Share | |||||
| Basic EPS | ($25.45) | ($50.50) | ($72.00) | ($129.00) | ($137.00) |
| Diluted EPS | ($25.45) | ($50.50) | ($72.00) | ($129.00) | ($137.00) |
| Revenue Per Share | $5.12 | $1.70 | $11.32 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.7M | 1.2M | 971467 | 955551 | 778545 |
| Diluted Shares Outstanding | 1.7M | 1.2M | 971467 | 955551 | 778545 |
| Profitability Metrics | |||||
| EBITDA | (29.2M) | (59.2M) | (68.9M) | (122.2M) | (105.3M) |
| D&A | 195.0K | 373.0K | 925.0K | 1.2M | 1.2M |
| EBIT | (29.4M) | (59.6M) | (69.8M) | (123.5M) | (106.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026